Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ex vivo-expanded allogeneic gamma 9 delta 2 T cells

A preparation of a subset of ex vivo-expanded, allogeneic T lymphocytes that express gamma 9 delta 2 T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the ex vivo-expanded allogeneic gamma 9 delta 2 T cells, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. Gamma 9 delta 2 T cells, a subset of gamma delta T cells, may have a stronger association with antitumor immune responses compared with other gamma delta T-cell subtypes.
Synonym:ex-vivo expanded allogeneic gamma9-delta2 T cells
Search NCI's Drug Dictionary